
Cigna Corp (NYSE:CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.
The Cigna Analyst: Ricky Goldwasser upgraded the rating for Cigna from Equal-Weight to Overweight, while raising the price target from $283 to $296.